Sunday, September 14th, 2025

SCB: Achieving Strong Profits Amid Strategic Restructuring and Market Challenges

Date: 24 October 2024
Broker: UOB Kay Hian


Overview

SCB X (Siam Commercial Bank) reported a net profit of Bt10.9 billion for the third quarter of 2024, reflecting a 13% increase year-on-year and a 9% increase quarter-on-quarter. The results exceeded both UOB Kay Hian’s and market expectations by 15% and 10%, respectively.

Financial Performance

  • Net Profit: Bt10.9 billion
  • Year-on-Year Change: +13%
  • Quarter-on-Quarter Change: +9%
  • PPOP: Declined by 1% year-on-year but was flat quarter-on-quarter.

Key Events

SCB recorded a loss of Bt731 million due to the sale of Purple Ventures and associated one-off impairment expenses of Bt797 million from the second quarter of 2024. This led to a total net impact of Bt1.5 billion related to the closure and sale of the Robinhood application.

Strategic Impact

The closure of the Robinhood application is expected to alleviate SCB’s operational burden by eliminating annual losses of Bt2 billion, as well as ongoing operating expenses associated with the application.

Outlook

Despite the challenges, SCB is positioned for future growth with a solid profit base and strategic restructuring aimed at improving efficiency and profitability.

Conclusion

SCB remains a key player in the Thai banking sector, demonstrating robust profit growth and strategic initiatives to optimize operations while navigating market challenges effectively.

today, Seatrium chart turns positive again.

On 12 November 2024 UOB Kay Hian wrote the following: Seatrium initiated a S\$100 million share buyback program on 4 June 2024, following a 20-for-1 share consolidation. To date, the company has spent S\$29...

Sino Biopharmaceutical Ltd Positioned for Strong Gains with Technical Buy Momentum

Date: September 17, 2024Broker: CGS-CIMB Securities Company Overview Sino Biopharmaceutical Ltd (Stock Code: 1177) is a major pharmaceutical company based in Hong Kong. It focuses on the research, development, production, and distribution of biopharmaceutical...

Tencent’s Strategic Growth Poised Amid Regulatory Easing and Market Optimism

Date of Report: October 28, 2024Broker: UOB Kay Hian Private Limited Investor Sentiment and Market Outlook for Tencent Investors are showing renewed optimism in Tencent, particularly in the context of China’s broader regulatory environment...